Genenta Science S.p.A. has announced a strategic partnership with ANEMOCYTE to advance the production of off-the-shelf lentiviral vector (LVV) Plasmid DNA. Building on their existing collaboration, the new agreement will leverage Genenta's robust, clinically validated LVV Plasmid DNA technology platform-originating from the research of Professor Luigi Naldini-to enhance ANEMOCYTE's offerings for advanced therapy programs. This partnership aims to provide reliable, high-quality plasmid DNA materials from research and development to commercial stages, supporting the scalable development of advanced therapies across the life science industry.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genenta Science S.p.A. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001134718-en) on October 24, 2025, and is solely responsible for the information contained therein.
Comments